Teplizumab For Diabetes Episode 315 – Real Life Pharmacology Podcast

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist

Education, Health & Fitness, Medicine

5 • 716 Ratings

🗓️ 22 February 2024

⏱️ 16 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Teplizumab is a relatively new agent that helps delay the progression of type 1 diabetes. It slows the rate of beta-cell destruction in the pancreas.

Teplizumab is associated with cytokine release syndrome which can result in flu-like symptoms of fever, aches, and headache.

Cytokine release syndrome due to teplizumab can be reduced by using appropriate pretreatment medications. Those medications can include analgesics, antihistamines, and/or antiemetics.

Teplizumab is associated with suppressing the immune system so it is ideal to get vaccinations completed before using this medication. I go over the specific recommendations in the podcast episode.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey all, welcome back to the Real Life Pharmacology podcast.
0:03.4	I'm your host pharmacist, Eric Christensen.
0:05.5	Thank you so much for listening today.
0:08.2	Go check out Real Life Pharmacology.com.
0:11.0	We've got your free 31-page PDF on the top 200 drugs.
0:15.5	Great study guide and refresher to have, no matter who you are.
0:18.9	If you're in pharmacy school, nursing school,
0:22.1	med school, taking pharmacology classes, you know, recently out in practice, need a little
0:27.8	refresher on things. Simply an email will get you access to that. So definitely go take advantage
0:33.8	of that where I lay out some of the most important clinical practice
0:37.7	pearls on the top 200 drugs. All right, let's get into the drug of the day today and
0:43.6	this is by request. It is to plizumab. So this is probably a fairly rare drug that you're
0:53.4	going to see used in your clinical practice.
0:57.3	If you work in diabetes, you're probably more likely to be able to see it here.
1:02.8	Brand name of this medication is T-Zield, and it is a monoclonal antibody and it is classified as an anti-CD3 antibody.
1:19.8	So mechanistically, what this medication does is it delays the onset of stage three type 1 diabetes. So it's typically given in
1:33.6	patients who have stage 2 type 1 diabetes. So this medication binds CD3, which CD3 is a cell surface antigen,
1:50.6	and those specific cells that that antigen is on,
1:55.8	that that CD3 antigen is on, is T cells. And more more specifically CD4 and CD8 T cells. Now what's important about these
2:09.0	T cells? So remember this is part of the immune system basically and if you remember
2:15.0	killer T cells from maybe some of your biology classes and things of that nature,
2:22.0	these are part of the immune system that destroy things, basically.
	...

Transcript will be available on the free plan in -404 days. Upgrade to see the full transcript now.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.